Results 61 to 70 of about 355,709 (346)

An RFC4/Notch1 signaling feedback loop promotes NSCLC metastasis and stemness

Nature Communications, 2021
Notch signaling represents a key mechanism mediating cancer metastasis and stemness. To understand how Notch signaling is overactivated to couple tumor metastasis and self-renewal in NSCLC cells, we performed the current study and showed that RFC4, a DNA
Lei Liu, Tianyu Tao, Shihua Liu, Xia Yang, Xuwei Chen, Jiaer Liang, Ruohui Hong, Wenting Wang, Yi Yang, Xiao-yin Li, Youhong Zhang, Quanfeng Li, Shujun Liang, Hao Yu, Yun Wu, Xinyu Guo, Yandong Lai, Xiao-Fan Ding, H. Guan, Jueheng Wu, Xun Zhu, Jie Yuan, Jun Li, Shicheng Su, Mengfeng Li, Xiuyu Cai, Junchao Cai, H. Tian   +27 more
semanticscholar   +1 more source

Prognostic value of microRNA-4521 in non-small cell lung cancer and its regulatory effect on tumor progression

Open Medicine, 2021
Non-small cell lung cancer (NSCLC) is a malignant tumor with the highest mortality rate in our country. It has been found in many studies that microRNA-4521 (miR-4521) is abnormally expressed and plays a role in clear cell renal cell carcinoma and other ...
Sun Butong, Cong Dan, Chen Kang, Bai Yuansong, Li Jun   +4 more
doaj   +1 more source

Non-invasive decision support for NSCLC treatment using PET/CT radiomics

Nature Communications, 2020
Two major treatment strategies employed in non-small cell lung cancer, NSCLC, are tyrosine kinase inhibitors, TKIs, and immune checkpoint inhibitors, ICIs.
W. Mu, Lei Jiang, Jianyuan Zhang, Yu-long Shi, J. Gray, I. Tunali, Chao Gao, Yingying Sun, Jie Tian, Xinming Zhao, Xilin Sun, R. Gillies, M. Schabath   +12 more
semanticscholar   +1 more source

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

Molecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton, Russell W. Madison, Candice Francheska B. Tambaoan, Funda Meric‐Bernstam, Christopher J. Sweeney, Razelle Kurzrock, Howard A. Burris III, David R. Spigel, Hanna Tukachinsky, Jason Hughes, Julia Malato, Bongin Yoo, Tania Szado, Cheryl Schwab, Lincoln W. Pasquina, Amaya Gasco, Katja Schulze, Claire F. Friedman   +17 more
wiley   +1 more source

EGFR Mutation Status and PD-L1 Expression in Patients ≤40 Years Old with NSCLC

Zhongliu Fangzhi Yanjiu, 2022
Objective To retrospectively analyze the clinical data of 47 young NSCLC patients mutation style of EGFR and PD-L1 expression in tumor cells, to understand their clinicopathological and molecular characteristics.
HU Mingming, LIU Zichen, ZHANG Hongmei, LU Baohua, LI Jie, WANG Qunhui, HU Fanbin, LIN Haifeng, LI Baolan, ZHANG Tongmei   +9 more
doaj   +1 more source

Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook

Molecular Cancer, 2020
Immunotherapy (IO) has revolutionized the therapy landscape of non-small cell lung cancer (NSCLC), significantly prolonging the overall survival (OS) of advanced stage patients.
L. Horvath, B. Thienpont, Liyun Zhao, D. Wolf, A. Pircher   +4 more
semanticscholar   +1 more source

EGFR‐STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1‐positive prostate cancer

Molecular Oncology, EarlyView.
Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva, Bernardo Orr, Ana Azeredo, Andreia Brandão, Manuel R. Teixeira, Paula Paulo   +5 more
wiley   +1 more source

Circ_0001944 Contributes to Glycolysis and Tumor Growth by Upregulating NFAT5 Through Acting as a Decoy for miR-142-5p in Non-Small Cell Lung Cancer

Cancer Management and Research, 2021
Yawei Dou,1 Wei Tian,1 Hongtao Wang,1 Shanshan Lv2 1Department of Thoracic Surgery, Shaanxi Province People’s Hospital, Xi’an, 710068, People’s Republic of China; 2Department of Cardiovascular Surgery, Xijing Hospital of Airforce ...
Dou Y, Tian W, Wang H, Lv S
doaj  

Integrative miRNOMe profiling reveals the miR‐195‐5p–CHEK1 axis and its impact on luminal breast cancer outcomes

Molecular Oncology, EarlyView.
In luminal (ER+) breast carcinoma (BC), miRNA profiling identified miR‐195‐5p as a key regulator of proliferation that targets CHEK1, CDC25A, and CCNE1. High CHEK1 expression correlates with worse relapse‐free survival after chemotherapy, especially in patients with luminal A subtype.
Veronika Boušková, Marie Ehrlichová, Alžběta Spálenková, Ivona Krus, Simona Šůsová, Viktor Hlaváč, Vlasta Němcová, Renata Koževnikovová, Markéta Trnková, David Vrána, Jiří Gatěk, Kateřina Kopečková, Marcela Mrhalová, Soňa Měšťáková, Pavel Souček   +14 more
wiley   +1 more source

The Expression of miR-320b in Extracellular Vesicles as a Predictor of the Progression of Non-small Cell Lung Carcinoma and Its Association with Molecular and Clinical Therapy Response

Forum of Clinical Oncology
Lung carcinoma remains a predominant contributor to cancer-related mortality globally. MicroRNAs (miRNAs) are pivotal regulators in carcinogenesis. Specifically, miR-320b is a tumor suppressor in the oncogenic process.
Ariawan Wily Pandu, Putra Andika Chandra, Sutandyo Noorwati, Pradipta Jaka, Pangaribuan Mariska TG, Hanafi Arif Riswahyudi, Jayusman Mulawarman, Hanif Muhammad Alfin, Hutabarat Jubillete Windy, Amira Salsabila Nur   +9 more
doaj   +1 more source